Marcelo Marotti

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer

Tony Mok, Yi‐Long Wu, M. Ahn et al. · QUT ePrints (Queensland University of Technology) · 2017 · 474 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

Elizabeth Fox, Richard Aplenc, Rochelle Bagatell et al. · Journal of Clinical Oncology · 2010 · 108 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Yi‐Long Wu, Roy S. Herbst, Helen Mann et al. · Clinical Lung Cancer · 2018 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17